A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Breast Cancer Patients Whose Disease Has Progressed on Endocrine Therapy in the Metastatic Setting (DESTINY-Breast06)

Status:

Opening Soon

III

Phase

3rd

Line of Therapy

Advanced / Metastatic

Disease Stage

Biomarker(s)

ER+, HER2-

Investigational

Product

Trastuzumab Deruxtecan (T-DXd)

Treatment Arms

o Experimental: Trastuzumab deruxtecan

o Active Comparator: Standard of Care